# CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

> **NCT03118180** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 50 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** CD19 targeted chimeric antigen receptor T cells

## Key facts

- **NCT ID:** NCT03118180
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-05
- **Primary completion:** 2018-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2017-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03118180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03118180, "CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03118180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*